Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 5/20 | 0.46 |
| ▸ | SIRT2 | Q8IXJ6 | 7/20 | 0.45 |
| ▸ | SIRT1 | Q96EB6 | 6/20 | 0.45 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.44 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3738065 | 0.92 | TLR2 (0.46) | TLR2SIRT2SIRT1SIRT3MBOAT4 | |
| SCHEMBL3733946 | 0.91 | TLR2 (0.43) | TLR2SIRT2SIRT1SIRT3MBOAT4 | |
| SCHEMBL3735763 | 0.89 | CTSD (0.42) | TLR2SIRT2SIRT1SIRT3MBOAT4 | |
| SCHEMBL3731860 | 0.88 | PRKCA (0.52) | TLR2SIRT2SIRT1SIRT3 | |
| SCHEMBL3728309 | 0.87 | TLR2 (0.47) | TLR2SIRT2SIRT1SIRT3CTSB | |
| SCHEMBL8134781 | 0.86 | TLR2 (0.46) | TLR2SIRT2SIRT1SIRT3CTSB | |
| SCHEMBL3732249 | 0.84 | TLR2 (0.49) | TLR2SIRT2SIRT1SIRT3CTSB | |
| SCHEMBL3732233 | 0.83 | SIRT2 (0.48) | SIRT2SIRT1SIRT3MBOAT4CTSB | |
| SCHEMBL3729465 | 0.81 | SIRT2 (0.48) | SIRT2SIRT1SIRT3CTSBCTSK | |
| SCHEMBL3730584 | 0.81 | PRKCA (0.52) | TLR2SIRT2SIRT1SIRT3CTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7825238-B2 | Antiviral methods employing double esters of 2′, 3′-dideoxy-3′-fluoroguanosine | MEDIVIR AB (SE) | 2010-11-02 | — | — | US | disclosed |
| US-7071173-B2 | Antiviral methods employing double esters of 2′, 3′-dideoxy-3′-fluoroguanosine | MEDIVIR AB (SE) | 2006-07-04 | — | — | US | disclosed |
| US-20060122383-A1 | Antiviral methods employing double esters of 2', 3'-dideoxy-3'-fluoroguanosine | MEDIVIR AB (SE) | 2006-06-08 | — | — | US | disclosed |
| US-20060058259-A1 | ANTIVIRAL METHODS EMPLOYING DOUBLE ESTERS OF 2', 3'-DIDEOXY-3'-FLUOROGUANOSINE | MEDIVIR AB (SE) | 2006-03-16 | — | — | US | disclosed |
| US-6974802-B2 | Treatment of viral infections using prodrugs of 2′,3-dideoxy,3′-fluoroguanosine | MEDIVIR AB (SE) | 2005-12-13 | — | — | US | disclosed |
| US-20030186924-A1 | Prodrugs | MEDIVIR AB | 2003-10-02 | — | — | US | disclosed |
| US-6458772-B1 | Prodrugs | MEDIVIR AB (SE) | 2002-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058259-A1 | ANTIVIRAL METHODS EMPLOYING DOUBLE ESTERS OF 2', 3'-DIDEOXY-3'-FLUOROGUANOSINE | UNG, HAVCR2, EIF2AK2 | TLR2 1859/4885SIRT2 2519/4885SIRT1 3697/4885 |
| US-20030186924-A1 | Prodrugs | HAVCR2, CYP7A1, IGSF11 | TLR2 1161/4885SIRT2 3823/4885SIRT1 2924/4885 |
| US-20060122383-A1 | Antiviral methods employing double esters of 2', 3'-dideoxy-3'-fluoroguanosine | UNG, HAVCR2, EIF2AK2 | TLR2 1859/4885SIRT2 2519/4885SIRT1 3697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.